Peripheral Artery Disease Management
Introduction to PAD Management
- The European Society of Cardiology recommends initiating comprehensive medical therapy immediately upon PAD diagnosis, including high-intensity statin therapy, antithrombotic therapy, supervised exercise training, aggressive blood pressure control, smoking cessation, and annual follow-up with vascular specialists 1, 2, 3
Lipid Management
- The American College of Cardiology recommends starting statin therapy immediately to achieve LDL-C <100 mg/dL, with a more aggressive target of <70 mg/dL reasonable for very high-risk PAD patients 4
- The European Society of Cardiology emphasizes intensive lipid lowering as foundational therapy 1
- Consider fibric acid derivatives for patients with low HDL, normal LDL, and elevated triglycerides 4
Antithrombotic Therapy
- The European Society of Cardiology recommends considering combination rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily for PAD patients with high ischemic risk and non-high bleeding risk 1, 2, 3, 5, 6
- This combination is also recommended following lower-limb revascularization in patients with non-high bleeding risk 1, 2, 3
- Aspirin 75-100 mg may be considered for primary prevention in asymptomatic PAD patients with diabetes 1, 2
Blood Pressure Control
- The American College of Cardiology recommends treating hypertension to achieve <140/90 mmHg, or <130/80 mmHg in patients with diabetes or chronic kidney disease 4, 7
- Beta-blockers are not contraindicated in PAD and are effective antihypertensives 4, 7
- ACE inhibitors may be considered to reduce adverse cardiovascular events 4, 7
Exercise Therapy
- The European Society of Cardiology recommends supervised exercise training as initial treatment, with walking training at high intensity, 3 times weekly, for at least 12 weeks 2, 3, 5, 6
- Alternative modes, such as strength training, arm cranking, or cycling, should also be considered 2
- Exercise to moderate-severe claudication pain may be considered to improve walking performance 2, 3
Smoking Cessation
- The American College of Cardiology recommends asking about tobacco use status at every encounter, providing counseling, and developing a quit plan with pharmacotherapy 4
- Offer one or more of: varenicline, bupropion, or nicotine replacement therapy, unless contraindicated 4
Diabetes Management
- The American College of Cardiology recommends targeting HbA1c <7% to reduce microvascular complications and potentially improve cardiovascular outcomes 4, 7
- Implement proper foot care immediately, including appropriate footwear, daily foot inspection, skin cleansing, topical moisturizing creams, and urgent attention to skin lesions/ulcerations 4, 7
Revascularization Considerations
- The European Society of Cardiology provides clear algorithmic guidance, recommending assessment of PAD-related quality of life after 3 months of optimal medical therapy and exercise therapy 1, 2, 3, 5, 6
- Revascularization may be considered only if quality of life remains impaired after this 3-month trial 1, 2, 3
- Revascularization is not recommended solely to prevent progression to chronic limb-threatening ischemia (CLTI) 1, 2, 3, 5, 6
Follow-Up Protocol
- The European Society of Cardiology recommends annual follow-up with a vascular specialist, assessing clinical/functional status, medication adherence, limb symptoms, and cardiovascular risk factors 1, 2, 3, 8, 5, 6, 9
- Coordinate care among multiple clinicians to optimize management of PAD and comorbid conditions 8, 9
- Periodic assessment of functional status and health-related quality of life is recommended 8, 9
- Long-term guideline-directed medical therapy to prevent major adverse cardiovascular events and major adverse limb events 8, 9
Post-Revascularization Surveillance
- The American College of Cardiology recommends ABI and arterial duplex ultrasound at 1-3 months, 6 months, 12 months, then annually, for both endovascular and autogenous vein bypass procedures 8, 9
- Immediate ABI and duplex ultrasound if new lower extremity signs or symptoms develop 8, 9